Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy-Reference-Cited by-同舟云学术

Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy

Published:2017-02-27 Issue:3 Volume:77 Page:468-470
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Le Burel Sébastien,Champiat Stéphane,Routier Emilie,Aspeslagh Sandrine,Albiges Laurence,Szwebel Tali-Anne,Michot Jean-Marie,Chretien Pascale,Mariette Xavier,Voisin Anne-Laure,Lambotte Olivier

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference6 articles.

1. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

3. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

4. Menzies AM , Johnson DB , Ramanujam S , et al . Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol 2016. doi: 10.1093/annonc/mdw443. pii: mdw443. doi:10.1093/annonc/mdw443

5. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Digital ischemia: a rare immune-related adverse event of immune checkpoint inhibitors—case report and review of the literature;Rheumatology International;2024-09-04

2. A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease;European Journal of Cancer;2024-08

3. Sicca syndrome/Sjögren’s disease associated with cancer immunotherapy: a narrative review on clinical presentation, biomarkers, and management;Expert Review of Clinical Immunology;2024-06-25

4. The Utility of Laboratory Investigations for the Assessment and Management of Rheumatic Immune Related Adverse Events;Rheumatic Disease Clinics of North America;2024-05

5. A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors;Italian Journal of Dermatology and Venereology;2023-11